Delix Therapeutics Phase I Trial for Novel Compound DLX-001

This Phase I clinical trial (n=100) will assess the safety, pharmacokinetics, psychometric functions, and markers of brain activity and synaptic plasticity of DLX-001, a non-hallucinogenic psychoplastogen developed by Delix Therapeutics.

The study will be conducted at the Center for Human Drug Research in the Netherlands, aiming to evaluate the therapeutic potential of psychoplastogens for treating psychiatric and neurological conditions. Delix’s innovative approach, led by co-founder David E. Olson, focuses on discovering non-hallucinogenic compounds that promote neuroplasticity, offering significant potential in mental health treatment. The trial marks a crucial advancement in neuroplasticity-promoting therapeutics, and is the first human trial of several psychoplastogens from Delix’s platform.

Dates and recruitment criteria are estimates until a trial is officially registered.

Topic Safety
Compound Ibogaine
Country Netherlands
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Delix Therapeutics
Delix Therapeutics is a drug development company focusing on novel psychedelic formulations.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.